- Shares of Geron (NASDAQ:GERN) are up 9% in premarket trading.
- Behind the move looks to be an article outlining a Mayo Clinic study which says imetelstat "has been found to induce morphologic, molecular, and clinical remissions in some patients with myelofibrosis."
- The study's lead author calls the results "early but promising."
- Amusingly, the article appears to have been posted ahead of its scheduled release from embargo.
- Full article is here
Mayo Clinic study boosts Geron
Recommended For You
About GERN Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
GERN | - | - |
Geron Corporation |